The impact of limited and strategic blood glucose monitoring on metabolic control in a type 1 diabetes clinic in Central India

2020 ◽  
Vol 40 (4) ◽  
pp. 578-584
Author(s):  
Caroline S. Zuijdwijk ◽  
Sharad Pendsey ◽  
James Ron ◽  
Graham D. Ogle ◽  
Amisha Agarwal ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Metabolic Control ◽  
Glucose Monitoring ◽  
Central India ◽  
Blood Glucose Monitoring ◽  
Diabetes Clinic ◽  
The Impact

Blood Glucose Monitoring Before and After Type 1 Diabetes Clinic Visits

2017 ◽  
Vol 44 (1) ◽  
pp. 32-39 ◽  
Author(s):  
Kimberly A Driscoll ◽  
Suzanne Bennett Johnson ◽  
Yuxia Wang ◽  
Nancy Wright ◽  
Larry C Deeb
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glucose Monitoring ◽  
Blood Glucose Monitoring ◽  
Diabetes Clinic ◽  
Before And After ◽  
Clinic Visits

The impact of real-time continuous glucose monitoring on metabolic control in children with type 1 diabetes

2020 ◽  
Author(s):  
Ruxandra Calapod Ioana ◽  
Irina Bojoga ◽  
Duta Simona Gabriela ◽  
Ana-Maria Stancu ◽  
Amalia Arhire ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real Time ◽  
Metabolic Control ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
The Impact

scholarly journals Hybrid Closed-Loop System Achieves Optimal Perioperative Glycemia in a Boy With Type 1 Diabetes: A Case Report

2021 ◽  
Vol 9 ◽  
Author(s):  
Jesus Dominguez-Riscart ◽  
Nuria Buero-Fernandez ◽  
Ana Garcia-Zarzuela ◽  
Fernando A. Marmolejo-Franco ◽  
Ana C. Perez-Guerrero ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Insulin Infusion ◽  
Closed Loop ◽  
Total Duration ◽  
Blood Glucose Monitoring ◽  
Medical Team ◽  
The Family ◽  
The Impact

The goal in type 1 diabetes (T1D) therapy is to maintain optimal glycemic control under any circumstance. Diabetes technology is in continuous development to achieve this goal. The most advanced Food and Drug Administration- and European Medicines Agency-approved devices are hybrid closed-loop (HCL) systems, which deliver insulin subcutaneously in response to glucose levels according to an automated algorithm. T1D is frequently encountered in the perioperative period. The latest international guidelines for the management of children with diabetes undergoing surgery include specific adjustments to the patient's insulin therapy, hourly blood glucose monitoring, and intravenous (IV) insulin infusion. However, these guidelines were published while the HCL systems were still marginal. We present a case of a 9-year-old boy with long-standing T1D, under HCL system therapy for the last 9 months, and needing surgery for an appendectomy. We agreed with the family, the surgical team, and the anesthesiologists to continue HCL insulin infusion, without further adjustments, hourly blood glucose checks or IV insulin, while monitoring closely. The HCL system was able to keep glycemia within range for the total duration of the overnight fast, the surgery, and the initial recovery, without any external intervention or correction bolus. This is, to the best of our knowledge, the first reported pediatric case to undergo major surgery using a HCL system, and the results were absolutely satisfactory for the patient, his family, and the medical team. We believe that technology is ripe enough to advocate for a “take your pump to surgery” message, minimizing the impact and our interventions. The medical team may discuss this possibility with the family and patients.

136-OR: Nocturnal Hypoglycemia Prevention Strategies Used by People with Type 1 Diabetes According to Their Insulin Delivery and Blood Glucose Monitoring Technology

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 136-OR
Author(s):  
MERYEM K. TALBO ◽  
VIRGINIE MESSIER ◽  
KATHERINE DESJARDINS ◽  
RÉMI RABASA-LHORET ◽  
ANNE-SOPHIE BRAZEAU ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glucose Monitoring ◽  
Insulin Delivery ◽  
Blood Glucose Monitoring ◽  
Prevention Strategies ◽  
Monitoring Technology ◽  
Nocturnal Hypoglycemia

scholarly journals Comparison between adherence assessments and blood glucose monitoring measures to predict A1c in type 1 diabetes

2015 ◽  
Vol 7 (S1) ◽  
Author(s):  
Gabriela Heiden Teló ◽  
Martina Schaan de Souza ◽  
Thaís Sturmer Andrade ◽  
Beatriz D'Agord Schaan
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glucose Monitoring ◽  
Blood Glucose Monitoring

scholarly journals Glycemic Control and Blood Glucose Monitoring Over Time in a Sample of Young Australians With Type 1 Diabetes: The role of personality

Diabetes Care ◽  
2013 ◽  
Vol 36 (10) ◽  
pp. 2968-2973 ◽  
Author(s):  
D. Waller ◽  
C. Johnston ◽  
L. Molyneaux ◽  
L. Brown-Singh ◽  
K. Hatherly ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glycemic Control ◽  
Glucose Monitoring ◽  
Blood Glucose Monitoring ◽  
Over Time

789-P: Self-Care for Blood Glucose Monitoring (BGM) in Teens with Type 1 Diabetes (T1D): Impact of Real-Time Positive and Negative Affect

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 789-P
Author(s):  
AMIT SHAPIRA ◽  
LISA K. VOLKENING ◽  
JOSHUA BORUS ◽  
LORI M. LAFFEL
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Negative Affect ◽  
Real Time ◽  
Glucose Monitoring ◽  
Self Care ◽  
Blood Glucose Monitoring ◽  
Positive And Negative Affect

Healthcare Utilization, Costs, and Adverse Events of Real-Time Continuous Glucose Monitoring (rtCGM) versus Traditional Blood Glucose Monitoring (BG) among US Adults with Type 1 Diabetes

2021 ◽  
pp. 193229682110315
Author(s):  
Benjamin Wong ◽  
Yalin Deng ◽  
Karen L. Rascati
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Adverse Events ◽  
Real Time ◽  
Healthcare Utilization ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Medical Costs ◽  
Blood Glucose Monitoring

Objective: To compare healthcare utilization, costs, and incidence of diabetes-specific adverse events (ie, hyperglycemia, diabetic ketoacidosis, and hypoglycemia) in type 1 diabetes adult patients using real-time continuous glucose monitoring (rtCGM) versus traditional blood glucose monitoring (BG). Methods: Adult patients (≥18 years old) with type 1 diabetes in a large national administrative claims database between 2013 and 2015 were identified. rtCGM patients with 6-month continuous health plan enrollment and ≥1 pharmacy claim for insulin during pre-index and post-index periods were propensity-score matched with BG patients. Healthcare utilization associated with diabetic adverse events were examined. A difference-in-difference (DID) method was used to compare the change in costs between rtCGM and BG cohorts. Results: Six-month medical costs for rtCGM patients ( N = 153) increased from pre- to post-index period, while they decreased for matched BG patients ( N = 153). DID analysis indicated a $2,807 ( P = .062) higher post-index difference in total medical costs for rtCGM patients. Pharmacy costs for both cohorts increased. DID analysis indicated a $1,775 ( P < .001) higher post-index difference in pharmacy costs for rtCGM patients. The incidence of hyperglycemia for both cohorts increased minimally from pre- to post-index period. The incidence of hypoglycemia for rtCGM patients decreased, while it increased marginally for BG patients. Inpatient hospitalizations for rtCGM and BG patients increased and decreased marginally, respectively. Conclusions: rtCGM users had non-significantly higher pre-post differences in medical costs but significantly higher pre-post differences in pharmacy costs (mostly due to the rtCGM costs themselves) compared to BG users. Changes in adverse events were minimal.

Sign in / Sign up

Export Citation Format

Share Document